Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

Blood (2017) 130 (Supplement 1): 1530.

https://doi.org/10.1182/blood.V130.Suppl_1.1530.1530

Published: 2017

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Thomas Noesslinger, MD, Michael Panny, MD, Michaela Moestl, MD, Elisabeth Koller, MD, Felix Keil, MD

Blood (2016) 128 (22): 2265.

https://doi.org/10.1182/blood.V128.22.2265.2265

Published: 2016

Journal Articles

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

Vincent Ribrag, MD, Khalil Saleh, MD, Alina Danu, MD, Serge Koscielny, Sylvain Pilorge, MD, Cristina castilla-Lorente, MD, David Ghez, Ph DMD, Julien Lazarovici, MD, Jean-Marie Michot, MD, Valerie Lapierre, PhD MD, Kamelia Alexandrova, Julia Arfi-Rouche, MD, Jean-Henri Bourhis, MD PhD

Blood (2016) 128 (22): 4648.

https://doi.org/10.1182/blood.V128.22.4648.4648

Published: 2016

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma

Roberto Crocchiolo, MD PhD, Luca Castagna, MD, Sabine Fuerst, MD, Jean El Cheikh, MD, Barbara Sarina, MD, Stefania Bramanti, Angela Granata, MD, Lucio Morabito, MD, Laura Giordano, MD, Sylvain Garciaz, MD, Diane Coso, MD, Reda Bouabdallah, MD, Monica Balzarotti, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Didier Blaise, MD PhD

Blood (2014) 124 (21): 3863.

https://doi.org/10.1182/blood.V124.21.3863.3863

Published: 2014

Journal Articles

Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis.

Justin Ching Ting Loke, BM BCh, Janice Ward, Prem Mahendra, Sridhar Chaganti, Ram Malladi

Blood (2012) 120 (21): 3088.

https://doi.org/10.1182/blood.V120.21.3088.3088

Published: 2012

Journal Articles

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium

AW Griffioen, CA Damen, GH Blijham, G Groenewegen

Blood (1996) 88 (2): 667–673.

https://doi.org/10.1182/blood.V88.2.667.bloodjournal882667

Published: 1996

NARROW

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma

Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis.

Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only